Bollard Group LLC Sells 345,870 Shares of Boston Scientific Corporation $BSX

Bollard Group LLC cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,733,573 shares of the medical equipment provider’s stock after selling 345,870 shares during the period. Boston Scientific comprises approximately 45.3% of Bollard Group LLC’s investment portfolio, making the stock its biggest holding. Bollard Group LLC owned approximately 1.33% of Boston Scientific worth $1,926,589,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Norges Bank purchased a new position in shares of Boston Scientific during the 2nd quarter valued at about $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $746,655,000. Parnassus Investments LLC boosted its position in Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP grew its stake in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $69.15 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a fifty day moving average of $82.47 and a 200 day moving average of $93.29. The firm has a market cap of $102.61 billion, a PE ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a one year low of $67.56 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% compared to the same quarter last year. During the same period last year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BSX. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. JPMorgan Chase & Co. lowered their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Royal Bank Of Canada dropped their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.